DSCM
CTKB icon

Divisadero Street Capital Management’s Cytek Biosciences CTKB Stock Holding History

Divisadero Street Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-487,550
Closed -$3.27M – 67
2024
Q1 		$3.27M Buy
+487,550
New +$3.86M 0.77% 30

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Divisadero Street Capital Management's CTKB Position: Q2 2024 in Review

Divisadero Street Capital Management sold out of Cytek Biosciences (CTKB) in Q2 2024, closing a stake of 487,550 shares — an estimated $3.27M sold.

Divisadero Street Capital Management first reported a position in CTKB in Q1 2024 and held it in 1 quarter. The position peaked at $3.27M in Q1 2024. 128 funds tracked by Wall St. Rank hold CTKB as of Q2 2024.

  • Divisadero Street Capital Management reported no remaining Cytek Biosciences position as of Q2 2024 after selling out during the quarter.
  • Divisadero Street Capital Management sold 487,550 Cytek Biosciences shares in Q2 2024, an estimated $3.27M.
  • Divisadero Street Capital Management first reported a position in Cytek Biosciences in Q1 2024 and held it in 1 quarter.
  • Divisadero Street Capital Management's Cytek Biosciences position peaked at $3.27M in Q1 2024.
  • 128 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2024.

Based on Divisadero Street Capital Management's 13F filing for Q2 2024, filed 12 Aug 2024.